A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

NCT03131687 · Completed

Last updated 2026-05-28

This clinical trial tests the medication tirzepatide in adults with type 2 diabetes to see how different doses affect blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 318 people

Who can join Ages 18–75 · all sexes

Timeline Started 2017-05 · est. completion 2018-08

Where 49 sites · Poland, Puerto Rico, Slovakia, United States

What this study is testing ClinicalTrials.gov NCT03131687 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.

Treatments tested

tirzepatide also known as LY3298176 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03131687 ↗